Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cytotoxic chemotherapy for metastatic renal cell carcinoma.

× No keyword cloud information.

9 in total

Review 1. Systemic therapy for renal cell carcinoma.

Authors: R J Motzer; P Russo
Journal: J Urol Date: 2000-02 Impact factor: 7.450

2. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer.

Authors: B I Rini; N J Vogelzang; M C Dumas; J L Wade; D A Taber; W M Stadler
Journal: J Clin Oncol Date: 2000-06 Impact factor: 44.544

3. A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma.

Authors: C M George; N J Vogelzang; B I Rini; F J Geoffroy; P Kollipara; W M Stadler
Journal: Ann Oncol Date: 2002-01 Impact factor: 32.976

4. Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group Study.

Authors: J A Kish; M Wolf; E D Crawford; J T Leimert; A Bueschen; J R Neefe; R C Flanigan
Journal: Cancer Date: 1994-08-01 Impact factor: 6.860

5. A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma.

Authors: Christopher W Ryan; Nicholas J Vogelzang; Walter M Stadler
Journal: Cancer Date: 2002-05-15 Impact factor: 6.860

6. Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer.

Authors: Walter M Stadler; Dezheng Huo; Christopher George; Ximing Yang; Christopher W Ryan; Theodore Karrison; Todd M Zimmerman; Nicholas J Vogelzang
Journal: J Urol Date: 2003-10 Impact factor: 7.450

7. A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma.

Authors: Apurva A Desai; Nicholas J Vogelzang; Brian I Rini; Rafat Ansari; Stuart Krauss; Walter M Stadler
Journal: Cancer Date: 2002-10-15 Impact factor: 6.860

8. Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group.

Authors: C A Townsley; K Chi; D S Ernst; K Belanger; I Tannock; G A Bjarnason; D Stewart; R Goel; J D Ruether; L L Siu; J Jolivet; L McIntosh; L Seymour; M J Moore
Journal: J Clin Oncol Date: 2003-04-15 Impact factor: 44.544

9. Gemcitabine in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group.

Authors: W C Mertens; E A Eisenhauer; M Moore; P Venner; D Stewart; A Muldal; D Wong
Journal: Ann Oncol Date: 1993-04 Impact factor: 32.976

9 in total

2 in total

1. A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma.

Authors: Elizabeth K Chung; Edwin M Posadas; Kristen Kasza; Theodore Karrison; Elizabeth Manchen; Olwen M Hahn; Walter M Stadler
Journal: Am J Clin Oncol Date: 2011-04 Impact factor: 2.339

2. VHL deficiency augments anthracycline sensitivity of clear cell renal cell carcinomas by down-regulating ALDH2.

Authors: Yao-Hui Gao; Zhao-Xia Wu; Li-Qi Xie; Cai-Xia Li; Yu-Qin Mao; Yan-Tao Duan; Bing Han; San-Feng Han; Yun Yu; Hao-Jie Lu; Peng-Yuan Yang; Tian-Rui Xu; Jing-Lin Xia; Guo-Qiang Chen; Li-Shun Wang
Journal: Nat Commun Date: 2017-06-15 Impact factor: 14.919

2 in total